Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kostrubsky, V. E.
Right arrow Articles by Davies, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kostrubsky, V. E.
Right arrow Articles by Davies, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 71, 282 (2003)
Copyright © 2003 by the Society of Toxicology

Letter

Vsevolod E. Kostrubsky, Ramin Rahbari, Alberto Lodola and Thomas Davies

Departments of Drug Safety Evaluation, Pfizer Global Research and Development, Ann Arbor, Michigan, 48105, and New London, Connecticut, 06320

The first 10% of the full text of this article appears below.

To the Editor:

In the article by Tirmenstein et al. (2002)Go the authors conclude that the initiating event in troglitazone (TRO) mediated toxicity to HepG2 cells is disruption of mitochondria. We agree with the authors that the relevance of their findings to idiosyncratic hepatotoxicity in TRO-treated . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?